An Enhanced Anti-Coagulant
Tech ID
P27-1210
Patent Status
Granted in India
Design Status
--
Technical Description
The invention introduces a novel anticoagulant formulation, known as Pegylated Dabigatran (PEG-DAB), offers improved pharmacokinetics and pharmacodynamics. It effectively prevents blood clot formation, reducing the risk of stroke and other complications. Notably, PEG-DAB also alleviates neurological deficits.
Problems Addressed
- Poor Aqueous Solubility
- Limited Bioavailability
- Non-specific Uptake
- Adverse Side Effects
- Requires High Doses
TARGET AUDIENCE
- Pharmaceutical Industry
- Healthcare Industry
- Hospitals and Clinics
- Biotechnology Industry
- Clinical Research Industry
TECH FEATURES
- Pegylated Anticoagulant Formulation
- Elevates Neurological Deficit
- Increased Aqueous Solubility
- Enhanced Anti-thrombotic Activity
- Enhanced Absorption
- Enhanced Stability
- High Bioavailability
- High Production Yield
P27-1210
Send download link to email.
Available For
Available for exclusive and non exclusive license
Sell off
Cost
—
Stage of Developments
Technology Validated
Contact Person
Mr. Lalit Ambastha
IP Bazzaar Technology Pvt. Ltd.
IP Bazzaar Technology Pvt. Ltd.
12 First Floor, National Park, Lajpat Nagar-IV,
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com